Identification of Novel Genomic Loci for Anxiety and Extensive Genetic Overlap with Psychiatric Disorders

Competing Interest Statement

Ole A. Andreassen is a consultant for Cortechs.ai and Precision Health and has received speaker honoraria from Lundbeck, Janssen, Otsuka and Sunovion. Srdjan Djurovic has received speakers honoraria from Lundbeck. Anders M. Dale was a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and the Mohn Medical Imaging and Visualization Centre in Bergen, Norway. He receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The other authors have no conflicts of interest to declare.

Funding Statement

We gratefully acknowledge support from the American National Institutes of Health (NS057198, EB00790), the Research Council of Norway (RCN) (296030, 324252, 324499, 300309, 273291, 223273), the South-East Norway Regional Health Authority (2022-073), The University of Oslo, and KG Jebsen Stiftelsen (SKGJ-MED-021). This project has received funding from the European Union Horizon 2020 research and innovation program under grant agreements No 847776, 964874, and 801133 under the Marie Skłodowska-Curie grant. The MoBa study is research is part of the HARVEST collaboration, supported by the Research Council of Norway (229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (223273), South East Norway Health Authorities and Stiftelsen Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research, the University of Bergen for providing genotype data and performing quality control and imputation of the data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The MoBa cohort has initially been approved by the Norwegian Data Protection Agency and The Regional Committees for Medical and Health Research Ethics in Norway and is currently regulated by the Norwegian Health Registry Act. The use of MoBa data for this work was approved under (REK 2016/1226). Individual studies comprising the published datasets have been approved by their respective ethical approval committees. This research was conducted according to the Helsinki Declaration.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes